TrialBreast cancer research : BCR2018

Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer.

Nadine Norton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.